<DOC>
	<DOCNO>NCT00915590</DOCNO>
	<brief_summary>The purpose study determine effectiveness safety topical Interleukin-1-Receptor Antagonist treatment corneal neovascularization .</brief_summary>
	<brief_title>Topical IL-1-Ra Treatment Corneal Neovascularization</brief_title>
	<detailed_description />
	<mesh_term>Neovascularization , Pathologic</mesh_term>
	<mesh_term>Corneal Neovascularization</mesh_term>
	<mesh_term>Interleukin 1 Receptor Antagonist Protein</mesh_term>
	<criteria>Ability provide write informed consent comply study assessment full duration study Age &gt; 18 year Patients superficial deep corneal NV extend far 1 mm limbus Patients generally good stable overall health • Has receive treatment antiVEGF agent ( topical , intraocular systemic ) within 30 day study entry Corneal ocular surface infection within 30 day prior study entry• Ocular periocular malignancy Contact lens ( exclude bandage contact lens ) use within 2 week prior study entry Persistent epithelial defect ( &gt; 1mm ≥14 day duration ) within 2 week prior study entry Intravitreal periocular steroid within 2 week prior study entry Change dose/frequency topical steroid and/or NSAIDs within 2 week prior study entry Pregnancy ( positive pregnancy test ) lactation Premenopausal woman use contraception Signs current infection , include fever current treatment antibiotic Participation another simultaneous medical investigation trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
</DOC>